SHTDF (Sinopharm Group Co) Cyclically Adjusted Price-to-FCF: (As of Sep. 21, 2026)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

SHTDF Sinopharm Group Co Ltd SHTDF
74 GF Score
Price $1.82
GF Value $2.72
Valuation Significantly Undervalued
! 3 Warning Signs
View Full Analysis

What is Sinopharm Group Co Cyclically Adjusted Price-to-FCF?

Shiller PE for Stocks: The True Measure of Stock Valuation


Sinopharm Group Co  (OTCPK:SHTDF) Cyclically Adjusted Price-to-FCF Explanation

Compared with the regular Price-to-Free-Cash-Flow, which works poorly for cyclical businesses, the Cyclically Adjusted Price-to-FCF smoothed out the fluctuations of free cash flow during business cycles. Therefore it is more accurate in reflecting the valuation of the company.

If a company has consistent business performance, the Cyclically Adjusted Price-to-FCF should give similar results to regular Price-to-Free-Cash-Flow.


Sinopharm Group Co Cyclically Adjusted Price-to-FCF Related Terms


Sinopharm Group Co Cyclically Adjusted Price-to-FCF Historical Data

* Premium members only.

The historical data trend for Sinopharm Group Co's Cyclically Adjusted Price-to-FCF can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Sinopharm Group Co Cyclically Adjusted Price-to-FCF Chart

Sinopharm Group Co Annual Data
Trend Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
Cyclically Adjusted Price-to-FCF
Get a 7-Day Free Trial Premium Member Only Premium Member Only 10.09 8.82 7.76 8.83 9.92

Sinopharm Group Co Semi-Annual Data
Dec16 Jun17 Dec17 Jun18 Dec18 Jun19 Dec19 Jun20 Dec20 Jun21 Dec21 Jun22 Dec22 Jun23 Dec23 Jun24 Dec24 Jun25 Dec25 Jun26
Cyclically Adjusted Price-to-FCF Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 30.34 10.21 26.02 11.71 6.41

SHTDF vs MCK, COR, CAH: Cyclically Adjusted Price-to-FCF Comparison

For the Medical Distribution subindustry, Sinopharm Group Co's Cyclically Adjusted Price-to-FCF, along with its competitors' market caps and Cyclically Adjusted Price-to-FCF data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Sinopharm Group Co Cyclically Adjusted Price-to-FCF vs Medical Distribution Industry

For the Medical Distribution industry and Healthcare sector, Sinopharm Group Co's Cyclically Adjusted Price-to-FCF distribution charts can be found below:

* The bar in red indicates where Sinopharm Group Co's Cyclically Adjusted Price-to-FCF falls into.


SHTDF
74GF Score
Sinopharm Group Co Ltd SHTDF
Cyclically Adjusted Price-to-FCF is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Sinopharm Group Co Cyclically Adjusted Price-to-FCF Calculation

Like the Shiller PE Ratio, the Cyclically Adjusted Price-to-FCF takes the Free Cash Flow per Share from the past 10 years, adjusts it for inflation, and then calculates the average. This average is then used for the P/FCF calculation. Because it considers this 10-year average, it's often referred to as the CAPFCF Ratio.

The Shiller PE Ratio was first used by professor Robert Shiller to measure the valuation of the overall market. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted Price-to-FCF.

Sinopharm Group Co's Cyclically Adjusted FCF per Share for the fiscal year that ended in Dec25 is calculated as:

For example, Sinopharm Group Co's adjusted Free Cash Flow per Share data for the fiscal year that ended in Dec25 was:

Adj_FreeCashFlowPerShare=Free Cash Flow per Share/CPI of Dec25 (Change)*Current CPI (Dec25)
=0.475/115.8323*115.8323
=0.475

Current CPI (Dec25) = 115.8323.

Sinopharm Group Co Annual Data

Free Cash Flow per Share CPI Adj_FreeCashFlowPerShare
201612 0.339 102.600 0.383
201712 -0.052 104.500 -0.058
201812 -0.160 106.500 -0.174
201912 0.577 111.200 0.601
202012 0.237 111.500 0.246
202112 0.157 113.108 0.161
202212 0.695 115.116 0.699
202312 0.526 114.781 0.531
202412 -0.241 114.893 -0.243
202512 0.475 115.832 0.475

Add all the adjusted free cash flow per share together and divide 10 will get our Cyclically Adjusted FCF per Share.

Please note that we use the CPI data of the country/region where the company is headquartered. If the CPI data for that country/region is not available, then we will use the CPI data of the United States as default.

Is Sinopharm Group Co (SHTDF) Overvalued in 2026?

Based on GuruFocus' analysis, Sinopharm Group Co stock appears to be undervalued. The current stock price of $1.82 is trading 33.2% below its estimated GF Value™ of $2.72. GuruFocus considers Sinopharm Group Co to be Significantly Undervalued.

Key valuation signals for SHTDF:

  • Cyclically Adjusted Price-to-FCF:
  • GF Value™: $2.72 vs. price of $1.82 (33.2% below fair value)
  • GF Score™: 74/100 with 3 warning signs

No single metric tells the full story. See the SHTDF stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.


Sinopharm Group Co Business Description

Address No. 385, East Longhua Road, Sinopharm Group Building, Huangpu District, Shanghai, CHN, 200023
Founded in 2003, Sinopharm is the largest wholesaler and retailer of drugs and medical devices in China and listed on the Hong Kong Stock Exchange in 2009. It is a core subsidiary of China National Pharmaceutical Group. Sinopharm's largest operating segment is pharmaceutical distribution, making up over 70% of its total revenue by the end of 2024. In 2018, Sinopharm acquired the largest Chinese medical device distributor, China National Scientific Instruments and Materials. Now, medical device distribution accounts for over 20% of Sinopharm's total revenue. Sinopharm's downstream customers range from hospitals and other health services institutions to end-customers.
74GF Score

Get the complete analysis for SHTDF

Cyclically Adjusted Price-to-FCF is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$1.82
Price
$2.72
GF Value